Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kanfer

Showing results (331-340 of 374) with videos related to

Pageof 38
Sort By:
Blood|December 23, 1999
Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemiaF Dazzi, R M Szydlo, C Craddock, et al.
British Journal of Haematology|February 13, 2001
Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxisC Craddock, R M Szydlo, F Dazzi, et al.
Clinical Pharmacokinetics|August 20, 2016
Open Flow Microperfusion as a Dermal Pharmacokinetic Approach to Evaluate Topical BioequivalenceManfred Bodenlenz, Katrin I Tiffner, Reingard Raml, et al.
British Journal of Haematology|February 23, 1999
CD34+-selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: tumour cell contamination and outcomeD Gupta, A Bybee, F Cooke, et al.
Bone Marrow Transplantation|March 10, 2015
Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working PartyK Horstmann, A Boumendil, J Finke, et al.
Bone Marrow Transplantation|February 28, 2006
Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patientsD O'Shea, C Giles, E Terpos, et al.
ACS Chemical Biology|August 2, 2017
Peptide-Membrane Interaction between Targeting and LysisKatharina Stutz, Alex T Müller, Jan A Hiss, et al.
Molecular Pharmaceutics|February 23, 2012
Provisional biopharmaceutical classification of some common herbs used in Western medicineSarah Waldmann, May Almukainzi, Nadia Araci Bou-Chacra, et al.
Leukemia|February 11, 2005
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapseD Marin, J Kaeda, R Szydlo, et al.
British Journal of Haematology|December 12, 2001
Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapseT I Mughal, A Yong, R M Szydlo, et al.
Pageof 38

Showing results (331-340 of 374) with videos related to

Sort By:
Pageof 38
Blood|December 23, 1999
Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemiaF Dazzi, R M Szydlo, C Craddock, et al.
British Journal of Haematology|February 13, 2001
Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxisC Craddock, R M Szydlo, F Dazzi, et al.
Clinical Pharmacokinetics|August 20, 2016
Open Flow Microperfusion as a Dermal Pharmacokinetic Approach to Evaluate Topical BioequivalenceManfred Bodenlenz, Katrin I Tiffner, Reingard Raml, et al.
British Journal of Haematology|February 23, 1999
CD34+-selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: tumour cell contamination and outcomeD Gupta, A Bybee, F Cooke, et al.
Bone Marrow Transplantation|March 10, 2015
Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working PartyK Horstmann, A Boumendil, J Finke, et al.
Bone Marrow Transplantation|February 28, 2006
Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patientsD O'Shea, C Giles, E Terpos, et al.
ACS Chemical Biology|August 2, 2017
Peptide-Membrane Interaction between Targeting and LysisKatharina Stutz, Alex T Müller, Jan A Hiss, et al.
Molecular Pharmaceutics|February 23, 2012
Provisional biopharmaceutical classification of some common herbs used in Western medicineSarah Waldmann, May Almukainzi, Nadia Araci Bou-Chacra, et al.
Leukemia|February 11, 2005
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapseD Marin, J Kaeda, R Szydlo, et al.
British Journal of Haematology|December 12, 2001
Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapseT I Mughal, A Yong, R M Szydlo, et al.
Pageof 38